Transcranial Magnetic Stimulation (TMS) for Depression and Other Mental Health Conditions

Transcranial magnetic stimulation (TMS) is a non-invasive brain stimulation technique that uses focused magnetic pulses — similar in strength to an MRI — to stimulate targeted regions of the brain. A magnetic coil is placed against the scalp, and brief electromagnetic pulses pass through the skull to activate neurons in specific cortical areas.

For depression treatment, the standard target is the left dorsolateral prefrontal cortex (DLPFC), a region consistently found to be underactive in people with major depressive disorder. By repeatedly stimulating this area, TMS restores more typical patterns of brain activity and connectivity.

The U.S. Food and Drug Administration first cleared TMS for treatment-resistant depression in 2008, following pivotal trials demonstrating its efficacy in patients who had failed prior medication trials. Since then, FDA clearances have expanded:

• Obsessive-compulsive disorder (OCD) — cleared in 2018, targeting the medial prefrontal cortex and anterior cingulate
• Smoking cessation — cleared in 2020, using deep TMS to reduce cravings
• Anxious depression — cleared in 2021

Research is also ongoing for PTSD, generalized anxiety, substance use disorders, and chronic pain, though these remain off-label applications. TMS represents one of the most significant advances in treatment-resistant depression management in the past two decades.

The efficacy data for TMS in treatment-resistant depression are strong, particularly given the difficulty of treating this population. These are patients who, by definition, have not responded adequately to at least one — and often several — antidepressant medications.

Across large trials and meta-analyses, the numbers are consistent:

• Response rates (≥50% symptom reduction): approximately 50–60% of patients
• Remission rates (minimal or no remaining symptoms): approximately 30–35% of patients

To put this in perspective, in antidepressant medication trials for treatment-resistant depression, remission rates with a next-step medication typically fall between 10–15%. A 30–35% remission rate in this population represents a meaningful clinical advance.

A 2019 meta-analysis published in The Lancet Psychiatry examined 81 randomized controlled trials and confirmed that active TMS significantly outperformed sham stimulation across multiple protocols. The effect sizes were moderate but clinically significant.

Durability is also encouraging. Studies suggest that roughly 60–70% of responders maintain their gains at 12 months. When relapse does occur, retreatment courses — often shorter than the initial course — tend to recapture the original response. Some clinics now offer periodic maintenance sessions to sustain remission.

Newer accelerated protocols, discussed below, are producing even more striking initial results, though long-term replication studies are still underway.

TMS has evolved considerably since its first FDA clearance. Four main protocols are now available, each with distinct characteristics:

1. Repetitive TMS (rTMS) — The Standard Protocol

This is the original and most widely studied form. A figure-8 coil delivers high-frequency (10 Hz) pulses to the left DLPFC. Each session lasts approximately 37 minutes, and a full course involves 30–36 sessions over 4–6 weeks (five days per week). This remains the most commonly used protocol and has the deepest evidence base.

2. Deep TMS (dTMS)

Deep TMS uses a specialized H-coil housed inside a helmet-like device that generates broader electromagnetic fields capable of reaching deeper brain structures — up to about 4 cm below the surface compared to 1.5–2 cm with standard coils. This is the protocol FDA-cleared for OCD and smoking cessation.

3. Theta Burst Stimulation (TBS)

Theta burst delivers patterned pulses that mimic the brain's natural theta rhythms, achieving equivalent stimulation in approximately 3 minutes per session rather than 37. A landmark 2018 trial in The Lancet (the THREE-D study) demonstrated that intermittent TBS was non-inferior to standard rTMS for depression.

4. Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT)

SAINT uses functional MRI-guided targeting and delivers 10 theta burst sessions per day over 5 consecutive days (50 total sessions). Initial Stanford data showed a striking 79% remission rate. This protocol received FDA clearance in 2022 and is now commercially available, though not yet widely offered.

TMS works through a well-characterized chain of neurophysiological events. When the magnetic coil discharges, it creates a rapidly changing magnetic field that passes painlessly through the skull. This field induces small electrical currents in cortical tissue, sufficient to depolarize neurons and trigger action potentials.

A single pulse produces a transient effect. The therapeutic value comes from repeated stimulation over multiple sessions, which produces lasting changes through several mechanisms:

• Normalization of the prefrontal-limbic circuit: In depression, the left DLPFC is typically hypoactive while limbic structures like the amygdala are hyperactive — an imbalance that maps onto reduced executive control over emotional reactivity. Repeated TMS to the left DLPFC restores prefrontal activity and, through downstream connectivity, dampens excessive limbic activation.
• Enhanced neuroplasticity: Repeated stimulation induces long-term potentiation (LTP)-like changes at the synapse, strengthening neural connections in targeted circuits. This process mirrors the mechanisms by which learning and memory are consolidated.
• Increased brain-derived neurotrophic factor (BDNF): Animal and human studies show TMS upregulates BDNF expression, a protein that supports neuronal survival and growth — notably, the same protein increased by antidepressants and exercise.
• Modulation of neurotransmission: TMS increases dopamine and serotonin release in prefrontal and subcortical regions, partially overlapping with the mechanisms of antidepressant medications.

Precision in coil placement matters. Newer protocols use functional MRI-based targeting to identify the specific DLPFC subregion most strongly anti-correlated with the subgenual cingulate, a node associated with depressive symptoms.

TMS is an outpatient procedure that requires no anesthesia, no sedation, and no recovery time. You sit in a reclined chair — similar to a dentist's chair — fully awake and alert throughout the session.

During the first visit, the technician performs a motor threshold calibration: the coil is positioned over the motor cortex and activated at gradually increasing intensities until your thumb or fingers twitch involuntarily. This determines your individual stimulation intensity, which is then used to calibrate treatment at the DLPFC target.

During treatment, you'll feel a repetitive tapping or knocking sensation on your scalp at the site of the coil. Many patients describe it as someone flicking the same spot on your head repeatedly. The first few sessions can be uncomfortable — sometimes described as a 4–6 out of 10 on a discomfort scale — but most people habituate within the first week.

The most common side effects are:

• Headache — reported by approximately 30–40% of patients, usually mild and responsive to over-the-counter analgesics
• Scalp discomfort at the stimulation site — tends to diminish with successive sessions
• Lightheadedness — transient, occurring in a small minority

The most serious potential adverse event is seizure, which occurs in fewer than 1 in 10,000 sessions — a rate comparable to many antidepressant medications. There are no systemic side effects: no weight gain, no sexual dysfunction, no cognitive impairment. Most patients drive themselves to and from sessions and return to work or daily activities immediately afterward.

TMS is primarily indicated for adults with major depressive disorder who have not responded adequately to at least one antidepressant medication given at sufficient dose and duration. In clinical practice, many patients referred for TMS have tried two or more medications. You do not need to stop current medications — TMS is frequently used as an adjunct to ongoing pharmacotherapy and psychotherapy.

Good candidates typically meet these criteria:

• Diagnosis of major depressive disorder (moderate to severe)
• Documented failure of at least one adequate antidepressant trial
• Ability to commit to a daily treatment schedule (weekdays for 4–6 weeks for standard protocols, or 5 consecutive days for accelerated protocols)
• No contraindications (see below)

Contraindications include:

• Ferromagnetic implants near the head — cochlear implants, metallic plates, aneurysm clips, or bullet fragments in or near the skull. Dental fillings and braces are generally safe.
• History of seizures or epilepsy — though some clinicians will consider TMS in controlled epilepsy with careful risk-benefit analysis
• Implanted stimulation devices — vagus nerve stimulators, deep brain stimulators, or cardiac pacemakers/defibrillators near the coil

Patients with bipolar disorder require careful evaluation, as stimulation can theoretically precipitate mania, though this is rare. TMS for OCD follows a different protocol and target, so a specific evaluation for that indication is needed.

Cost remains one of the most significant barriers to TMS. A full course of standard rTMS (30–36 sessions) typically ranges from $6,000 to $12,000 out of pocket. Accelerated protocols like SAINT may carry similar or higher costs due to the imaging and intensive scheduling involved.

Insurance coverage has expanded substantially since 2008. Most major commercial insurers, Medicare, and many state Medicaid programs now cover TMS for treatment-resistant depression — but approval typically requires documentation of failed medication trials (usually at least two), and prior authorization is almost always required. Coverage for OCD and smoking cessation is less consistent.

Practical considerations for access:

• Availability varies by region. TMS devices are concentrated in urban and suburban areas. Rural access remains limited, though the number of providers has grown steadily — from roughly 700 clinics in 2015 to over 2,000 in 2023.
• Time commitment is real. Standard rTMS requires daily weekday visits for 4–6 weeks. For someone working full-time, this means negotiating time off or adjusting schedules. Theta burst (3-minute sessions) and SAINT (5-day protocol) reduce this burden considerably.
• Ask about financing. Many TMS clinics offer payment plans. Some manufacturers run patient assistance programs.

When evaluating a provider, ask about their protocol (what type of TMS they offer), targeting method (anatomical landmark vs. neuronavigation vs. fMRI-guided), practitioner experience (number of patients treated), and outcome tracking (whether they systematically measure symptom change with validated instruments like the PHQ-9).